Review of the Novel Investigational Antifungal Olorofim
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The incidence of invasive fungal infections caused by molds and endemic fungi is increasing. There is also concern regarding increased rates of reduced susceptibility or frank resistance among Aspergillus and Coccidioides species, while Scedosporium species, Lomentospora prolificans, and Fusarium species are inherently less susceptible or intrinsically resistant to clinically available antifungals. Olorofim (formerly F901318) is the first member of the orotomide class of antifungals to be evaluated clinically for the treatment of invasive mold infections. This agent inhibits dihydroorotate dehydrogenase, a key enzyme in the biosynthesis of pyrimidines. Olorofim has activity against many molds and thermally dimorphic fungi, including species that are resistant to azoles and amphotericin B, but lacks activity against yeasts and the Mucorales. It is currently being developed for both oral and intravenous administration. Although published clinical outcome data have been limited to case reports to date, the results against invasive and refractory infections are promising. This review describes the mechanism of action of olorofim, its in vitro spectrum of activity, and what is currently known about its pharmacokinetic profile and clinical efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pappas, P. G., Alexander, B. D., Andes, D. R., Hadley, S., Kauffman, C. A., Freifeld, A., Anaissie, E. J., Brumble, L. M., Herwaldt, L., Ito, J., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651262 · Cited by 1,570
Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Ito, J., Andes, D. R., Baddley, J. W., Brown, J. M., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651263 · Cited by 1,456
The Fungal Cell Wall: Structure, Biosynthesis, and Function
Gow, N. A. R., Latge, J.-P., & Munro, C. A. (2017) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0035-2016 · Cited by 1,423 · cited 2×
“UTP is required for the formation of UDP-sugars, which are substrates for 1,3-βD-glucan synthase and chitin synthase (which are responsible for synthesis of the cell wall components 1,3-β-D-glucan and chitin, respectively) [26].”
BackgroundNeofytos, D., Horn, D., Anaissie, E., Steinbach, W., Olyaei, A., Fishman, J., Pfaller, M., Chang, C., Webster, K., & Marr, K. (2009) · Clinical Infectious Diseases · doi:10.1086/595846 · Cited by 801
Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma
Smith, N. L., & Denning, D. W. (2011) · European Respiratory Journal · doi:10.1183/09031936.00054810 · Cited by 449
F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., du Pré, S., Livermore, J., Bromley, M. J., Wiederhold, N. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608304113 · Cited by 289
Self-citationLewis, R. E., Wiederhold, N. P., & Klepser, M. E. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.945-951.2005 · Cited by 129
Self-citationdu Pré, S., Beckmann, N., Almeida, M. C., Sibley, G. E. M., Law, D., Brand, A. C., Birch, M., Read, N. D., & Oliver, J. D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00231-18 · Cited by 111 · cited 5×
“Thus, inhibition of pyrimidine synthesis by olorofim may affect the fungal cell wall and result in cell lysis [27].”
BackgroundResultInfluentialWiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Birch, M., Law, D., Rex, J. H., Catano, G., & Patterson, T. F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00999-18 · Cited by 80 · cited 2×
“Olorofim has also been reported to have activity against Microascus and Scopulariopsis species (which frequently have reduced susceptibility to the azoles), as well as Acremonium species, Paecilomyces variotii (which has reduced susceptibility to voriconazole), Purpureocillium lilacinum (which is intrinsically resista…”
BackgroundSelf-citationCota, J. M., Grabinski, J. L., Talbert, R. L., Burgess, D. S., Rogers, P. D., Edlind, T. D., & Wiederhold, N. P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01542-07 · Cited by 69
Self-citation
Cited by
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
Hoenigl, M., Sprute, R., Egger, M., Arastehfar, A., Cornely, O. A., Krause, R., Lass-Flörl, C., Prattes, J., Spec, A., Thompson, G. R., et al. (2021) · Drugs · doi:10.1007/s40265-021-01611-0 · Cited by 467
Self-citationEmerging Antifungal Targets and Strategies
Ivanov, M., Ćirić, A., & Stojković, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052756 · Cited by 160
Brüggemann, R. J., Verheggen, R., Boerrigter, E., Stanzani, M., Verweij, P. E., Blijlevens, N. M. A., & Lewis, R. E. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00232-5 · Cited by 67
Antifungals in Clinical Use and the Pipeline
Johnson, M. D. (2021) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2021.03.005 · Cited by 35
Investigational Agents for the Treatment of Resistant Yeasts and Molds
Seiler, G. T., & Ostrosky-Zeichner, L. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00419-5 · Cited by 32
Metadata
- Authors
- Wiederhold, N. P.
- Venue
- Journal of Fungi
- Publisher
- MDPI AG
- Published
- 2020-07-30
- Volume
- 6
- Issue
- 3
- Pages
- 122
- ISSN
- 2309-608X (ISSN-L)
- OpenAlex
- W3046120299
- Cited by
- 155
- References
- 13
- FWCI
- 2.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review of the Novel Investigational Antifungal Olorofim. https://app.cochat.ai/papers/10.3390/jof6030122
- The paper
- Wiederhold, N. P. (2020). Review of the Novel Investigational Antifungal Olorofim. Journal of Fungi. https://doi.org/10.3390/jof6030122
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.